Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 7/2019

11.04.2019 | Original Article

Diagnostic performance of 18F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy

verfasst von: Boramy Hay, Denis Mariano-Goulart, Aurélie Bourdon, Meriem Benkiran, Fabien Vauchot, Delphine De Verbizier, Fayçal Ben Bouallègue

Erschienen in: Annals of Nuclear Medicine | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of our study was to assess the diagnostic performance of 18F-FDG PET-CT for large vessel involvement in patients with suspected giant cells arteritis (GCA) and a negative temporal artery biopsy (TAB).

Methods

We conducted a retrospective study in a cohort of patients with suspected GCA and negative TAB who underwent an 18F-FDG PET-CT. Ten vascular segments were studied using a visual score and a semi-quantitative method based on SUVmax ratio with respect to liver uptake. The diagnosis of GCA was established during a mean follow-up of 42 months, based on the presence of clinical symptoms, laboratory results, and imaging data compatible with GCA, good response to corticosteroid therapy, and no differential diagnosis after a follow-up of at least 18 months.

Results

We included 63 patients (30 men and 33 women, aged 67 ± 12 years). 18F-FDG PET-CT showed large vessel involvement in 22 patients, 14 of whom were finally diagnosed with GCA. Forty-one patients were 18F-FDG PET-CT negative, 9 of whom were finally diagnosed with GCA. Overall, 18F-FDG uptake by large vessel yielded 61% sensitivity, 80% specificity, 64% positive predictive value, 78% negative predictive value, and 73% diagnostic accuracy. A significant number of patients were treated by corticosteroids before 18F-FDG PET-CT. However, corticosteroid therapy did not impact significantly the diagnostic performance, although there was a trend to a lower sensitivity in patients receiving corticosteroid therapy for more than 3 days.

Conclusions

18F-FDG PET-CT is a useful imaging technique to assess large vessel involvement in patients with suspected GCA and negative TAB.
Literatur
1.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.CrossRefPubMed
2.
González-Gay MA, García-Porrua C, Llorca J, Gonzalez-Louzano C, Rodriguez- Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30:249–56.CrossRefPubMed
3.
Roth AM, Milsow L, Keltner JL. The ultimate diagnoses of patients undergoing temporal artery biopsies. Arch Ophtalmol. 1984;102:901–3.CrossRef
4.
Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–7.CrossRef
5.
Ozaki S, Ando M, Isobe M, Kobayashi S, Matsunaga N, Miyata T, et al. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J. 2011;75:474–503.CrossRef
6.
Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77:636–43.CrossRef
7.
Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.CrossRef
8.
Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170–6.CrossRefPubMed
9.
Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;15(55):131–7.CrossRef
10.
De Boysson H, Lambert M, Liozon E, Boutemy J, Maigné G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations: working diagnosis of a distinct disease pattern. Medicine (Baltimore). 2016;95:e3818.CrossRef
11.
Ninan J, Lester S, Hill C. Giant cell arteritis. Best Pract Res Clin Rheumatol. 2016;30:169–88.CrossRefPubMed
12.
Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015;94:e622.CrossRefPubMedPubMedCentral
13.
Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann K, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30:730–6.CrossRefPubMed
14.
Slart RHJA, Glaudemans AWJM, Chareonthaitawee P, Treglia G, Besson FL, Bley TA, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45:1250–69.CrossRefPubMedPubMedCentral
15.
Besson FL, de Boysson H, Parienti JJ, Bouvard G, Bienvenu B, Agostini D. Towards an optimal semiquantitative approach in giant cell arteritis: an (18)F-FDG PET/CT case-control study. Eur J Nucl Med Mol Imaging. 2014;41:155–66.CrossRefPubMed
16.
Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11:A544–54.CrossRefPubMed
17.
Mahr A, Saba M, Kambouchner M, Polivka M, Baudrimont M, Brochériou I, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65:826–8.CrossRefPubMedPubMedCentral
18.
Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128:211–5.CrossRefPubMed
19.
Narváez J, Bernad B, Roig-Vilaseca D, García-Gómez C, Gómez-Vaquero C, Juanola X, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37:13–9.CrossRefPubMed
20.
Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Eric L, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54:463–70.CrossRef
21.
Murchison AP, Gilbert ME, Bilyk JR, Eagle RC, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154:722–9.CrossRefPubMed
22.
23.
Rojo-Leyva F, Ratliff NB, Cosgrove DM, Hoffman GS. Study of 52 patients with idiopathic aortitis from a cohort of 1204 surgical cases. Arthritis Rheum. 2000;43:901–7.CrossRefPubMed
24.
Hernandez-Rodriguez J, Garcia-Martinez A, Espigol-Frigole G, Grau JM, Collado A, Cid MC. Sustained spontaneous clinical remission in giant cell arteritis: report of two cases with long-term follow up. Arthritis Rheum. 2006;55:160–2.CrossRefPubMed
25.
Purvin V, Kawasaki A. Giant cell arteritis with spontaneous remission. Clin Exp Ophthalmol. 2007;35:59–61.CrossRefPubMed
26.
Puppo C, Massollo M, Paparo F, Camellino D, Piccardo A, Shoushtari Zadeh Naseri M, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int. 2014;2014:574248.CrossRefPubMedPubMedCentral
27.
Besson FL, Parienti JJ, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:1764–72.CrossRefPubMed
28.
Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging. 2012;39:344–53.CrossRefPubMed
29.
Nielsen BD, Gormsen LC, Hansen IT, Keller KK, Therkildsen P, Hauge EM. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018;45:1119–28.CrossRefPubMed
30.
De Boysson H, Liozon E, Lambert M, Parienti JJ, Artigues N, Geffray L, et al. 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis A multicenter cohort of 130 patients. Medicine (Baltimore). 2016;95:e3851.CrossRef
Metadaten
Titel
Diagnostic performance of 18F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy
verfasst von
Boramy Hay
Denis Mariano-Goulart
Aurélie Bourdon
Meriem Benkiran
Fabien Vauchot
Delphine De Verbizier
Fayçal Ben Bouallègue
Publikationsdatum
11.04.2019
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 7/2019
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-019-01358-5

Weitere Artikel der Ausgabe 7/2019

Annals of Nuclear Medicine 7/2019 Zur Ausgabe

Original Article

Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma

Original Article

A novel biomarker, active whole skeletal total lesion glycolysis (WS-TLG), as a quantitative method to measure bone metastatic activity in breast cancer patients

Original Article

Development of anatomically and lesion contrast-guided partial volume correction: new 3D formalisms and validation in phantom and clinical studies

Original Article

Factors affecting accuracy of S values and determination of time-integrated activity in clinical Lu-177 dosimetry

Original Article

A systematic performance evaluation of head motion correction techniques for 3 commercial PET scanners using a reproducible experimental acquisition protocol

Short Communication

The severity of obstructive sleep apnea syndrome cannot predict the accumulation of brain amyloid by imaging with [11C]-Pittsburgh compound B PET computed tomography in patients with a normal cognitive function